Comparison between zotarolimus-eluting stents and first generation drug-eluting stents in the treatment of patients with acute ST-segment elevation myocardial infarction

International Journal of Cardiology

Volumn 166, Issue 1, 2013, Pages 118-125

  Park, Kyung Woo ^a   Lim, Woo Hyun ^a   Kim, Ji Hyun ^a   Kang, Si Hyuck ^a   Seo, Jung Won ^b   Song, Young Bin ^c   Hahn, Joo Yong ^c   Lee, Hae Young ^a   Kang, Hyun Jae ^a   Cho, Young Seok ^b   Youn, Tae Jin ^b   Koo, Bon Kwon ^a   Choi, Seung Hyuk ^c   Chae, In Ho ^b   Gwon, Hyeon Cheol ^c   Choi, Dong Ju ^b   Kim, Hyo Soo ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Cardiac and Vascular Center   (South Korea)

Author keywords

Drug eluting stent; Paclitaxel eluting stent; Sirolimus eluting stent; ST elevation myocardial infarction; Zotarolimus eluting stent

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

ACUTE HEART INFARCTION; ADULT; ANTICOAGULANT THERAPY; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE REGISTRY; DRUG ELUTING STENT; FEMALE; HEART DEATH; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PACLITAXEL; PERCUTANEOUS CORONARY INTERVENTION; REGISTRIES; RETROSPECTIVE STUDIES; SIROLIMUS; TREATMENT OUTCOME;

EID: 84877732642     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.10.012     Document Type: Article

References (26)

1. J.W. Moses, M.B. Leon, and J.J. Popma Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323
2. G.W. Stone, S.G. Ellis, and D.A. Cox A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231
3. S.V. Rao, R.E. Shaw, R.G. Brindis, L.W. Klein, W.S. Weintraub, and E.D. Peterson On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]) Am J Cardiol 97 2006 1478 1481
4. A.A. Bavry, D.J. Kumbhani, T.J. Helton, P.P. Borek, G.R. Mood, and D.L. Bhatt Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials Am J Med 119 2006 1056 1061
5. J. Daemen, P. Wenaweser, and K. Tsuchida Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678
6. G.W. Stone, J.W. Moses, and S.G. Ellis Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents N Engl J Med 356 2007 998 1008
7. A.A. Bavry, and D.L. Bhatt Acute myocardial infarction and drug-eluting stents: a green light for their use or time for measured restraint? Am Heart J 153 2007 719 721
8. G. Nakazawa, A.V. Finn, and M. Joner Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study Circulation 118 2008 1138 1145
9. T.L. Pinto Slottow, and R. Waksman Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on the endeavor zotarolimus-eluting coronary stent Circulation 117 2008 1603 1608
10. M. Joner, G. Nakazawa, and A.V. Finn Endothelial cell recovery between comparator polymer-based drug-eluting stents J Am Coll Cardiol 52 2008 333 342
11. K. Thygesen, J.S. Alpert, and H.D. White Universal definition of myocardial infarction Circulation 116 2007 2634 2653
12. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
13. J.R. Nebeker, R. Virmani, and C.L. Bennett Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project J Am Coll Cardiol 47 2006 175 181
14. A.V. Finn, M. Joner, and G. Nakazawa Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization Circulation 115 2007 2435 2441
15. R. Virmani Next generation DES: results from preclinical Data Summit TCT Asia Pacific 2008 2008
16. J.S. Kim, I.K. Jang, and C. Fan Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial JACC Cardiovasc Interv 2 2009 1240 1247
17. J.M. Sutton, S.G. Ellis, and G.S. Roubin Major clinical events after coronary stenting. The multicenter registry of acute and elective Gianturco-Roubin stent placement. The Gianturco-Roubin Intracoronary Stent Investigator Group Circulation 89 1994 1126 1137
18. D.W. Park, S.W. Park, and K.H. Park Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up Am J Cardiol 98 2006 352 356
19. H.K. Kim, M.H. Jeong, and Y.K. Ahn Comparison of outcomes between zotarolimus- and sirolimus-eluting stents in patients with ST-segment elevation acute myocardial infarction Am J Cardiol 105 2010 813 818
20. C.W. Lee, D.W. Park, and S.H. Lee Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction Am J Cardiol 104 2009 1370 1376
21. K.W. Park, Y.S. Cho, and J.W. Chung One year clinical and six month angiographic results of drug eluting stents for ST elevation acute myocardial infarction: 'real world' comparison between sirolimus- and paclitaxel-eluting stents Int J Cardiol 131 2009 350 355
22. Y. Cho, H.M. Yang, and K.W. Park Paclitaxel- versus sirolimus-eluting stents for treatment of ST-segment elevation myocardial infarction: with analyses for diabetic and nondiabetic subpopulation JACC Cardiovasc Interv 3 2010 498 506
23. J.H. Lee, H.S. Kim, and S.W. Lee Prospective randomized comparison of sirolimus- versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction: pROSIT trial Catheter Cardiovasc Interv 72 2008 25 32
24. M.B. Leon, L. Mauri, and J.J. Popma A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial J Am Coll Cardiol 55 2010 543 554
25. M.B. Leon, D.E. Kandzari, and E.L. Eisenstein Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) JACC Cardiovasc Interv 2 2009 1208 1218
26. D.E. Kandzari Five year clinical results from endeavor III: a randomized comparison of the zotarolimus-eluting versus sirolimus-eluting stents in de novo native coronary lesions J Am Coll Cardiol 55 2010 E1806